|1.||Nicolau, David P: 24 articles (01/2016 - 05/2003)|
|2.||Kuti, Joseph L: 17 articles (01/2016 - 04/2004)|
|3.||Lipman, Jeffrey: 15 articles (01/2016 - 04/2009)|
|4.||Roberts, Jason A: 15 articles (01/2016 - 07/2009)|
|5.||Wallis, Steven C: 6 articles (01/2016 - 01/2013)|
|6.||Morikawa, Norifumi: 6 articles (06/2015 - 07/2008)|
|7.||Ikawa, Kazuro: 6 articles (06/2015 - 07/2008)|
|8.||Pea, Federico: 5 articles (09/2015 - 07/2011)|
|9.||Cojutti, Piergiorgio: 5 articles (09/2015 - 07/2011)|
|10.||Udy, Andrew A: 5 articles (01/2015 - 02/2013)|
04/01/2002 - "With regard to the clinical efficacy and prevention of antibiotic resistance, meropenem monotherapy or combination therapy with aminoglycoside is the most superior treatment for pseudomonal infections, and the findings in this study suggest that meropenem is still clinically very useful."
09/01/2015 - "Continuous-infusion meropenem at dosages up to 90 mg/kg/day might be effective for optimal treatment of severe Gram-negative-related infections in pediatric HSCT patients, even when caused by carbapenem-resistant pathogens with an MIC of up to 8 mg/liter. "
08/01/2011 - "This is the first report of a meropenem-non-susceptible carbapenamase-positive Klebsiella pneumoniae blood stream infection treated successfully with high-dose, continuous-infusion meropenem. "
08/01/2011 - "High-dose, continuous-infusion meropenem achieved serum drug concentrations above the minimum inhibitory concentration and eradicated the infection. "
06/01/2004 - "Two patients with gram-negative CNS infections were treated successfully with high-dose, prolonged infusions of meropenem. "
06/01/2007 - "These results suggested that prolongation of infusion time of meropenem was usefu for improvement of the clinical efficacy against life-threatening pneumonia."
01/01/2015 - "Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study."
08/01/2004 - "The efficacy and tolerability of meropenem as empirical treatment in patients with hospital-acquired pneumonia was determined in a prospective, open-label, non-randomized trial. "
10/01/2015 - "Meropenem was prescribed most frequently in Intensive Care Unit (22%), and pneumonia was the most common diagnosis (35%). "
01/01/2015 - "A chest X-ray showed nodules and infiltrates in both lungs, and the patient was initially diagnosed with pneumonia and administered meropenem hydrate, although his symptoms did not improve. "
08/01/2013 - "Two and four doses of 40 mg/kg meropenem, for both of which %T>MIC was calculated as 100, had similar efficacy and were significantly superior to a single-dose of 40 mg/kg. In conclusion, meropenem had high efficacy when %T>MIC in the CSF was increased because of the high dose level and shortening of the dosing interval in a guinea pig meningitis model caused by Hib BLNAR, suggesting that high and frequent doses of meropenem are useful for treatment of meningitis with Hib BLNAR. "
12/01/2010 - "In this report, we present a case of postneurosurgical meningitis due to Providencia stuartii, which was treated successfully with meropenem therapy lasting 21 days."
09/01/1997 - "Meropenem may also be useful in the treatment of meningitis by Pseudomonas aeruginosa in which other treatments have failed."
08/01/2008 - "The aim of this study was to determine the efficacy of meropenem in two meningitis models and the possible influence of the animal model over results. "
07/01/1995 - "Efficacy of meropenem in experimental meningitis."
01/01/2010 - "Meropenem is effective and safe for treatment of FN in pediatric cancer patients."
03/01/1997 - "Furthermore, meropenem monotherapy has demonstrated efficacy in the empirical treatment of febrile neutropenic cancer patients. "
06/01/2003 - "With the limited data of the therapy in pediatric patients, the authors conducted this study to evaluate the efficacy and safety of meropenem as empirical antibiotic therapy in 30 pediatric cancer patients with FN (mean age = 7.5 years), who were admitted to King Chulalongkorn Memorial Hospital from May 2000 to December 2001. "
02/01/2009 - "High incidence of meropenem resistance among alpha-hemolytic streptococci in children with cancer."
06/01/2005 - "The results demonstrate that meropenem is effective and well-tolerated when used for the treatment of neutropenic cancer children."
01/01/2000 - "[The efficacy of meropenem in treating abdominal sepsis in surgical patients]."
01/01/2011 - "Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial."
07/01/2014 - "ESBL lethal sepsis (1.0x1010CFU/mL) was treated immediately with 50 mg/kg of meropenem every eight hours for 24 hours and presented 40% mortality compared with 80% mortality of the control group (p=0.033). "
06/01/2014 - "The patient who was diagnosed with sepsis was successfully treated with meropenem which was started empirically. "
01/01/2014 - "He had recurrent sepsis immediately after discontinuation of intravenous meropenem to which the ESBL was sensitive. "
|1.||imipenem drug combination cilastatin (Primaxin)
|8.||Carbapenems (Carbapenem Antibiotics)
|2.||Renal Replacement Therapy (Therapies, Renal Replacement)
|3.||Drug Therapy (Chemotherapy)
|4.||Renal Dialysis (Hemodialysis)